Abstract
Commentary: Sublingual Allergen Immunotherapy in HIV-Positive Patients
Highlights
Specialty section: This article was submitted to HIV and AIDS, a section of the journal Frontiers in Immunology
I read with great interest the Brief Communication by Iemoli et al, on the latest issue of Allergy, where the authors reported that HIV-patients, undergoing anti-retroviral therapy (HAART) and sublingual immunotherapy (SLIT) to grass-pollen allergy, reported clinical benefits
The authors evaluated the outcome by the analysis of total combined score (TCS) and a quality of life (QoL) questionnaire [1] and concluded that SLIT was clinically effective and safe and did not change any immune-virological parameter in HIV-infected individuals
Summary
Specialty section: This article was submitted to HIV and AIDS, a section of the journal Frontiers in Immunology. Patients underwent immunotherapy while being in active HAART for at least 5 years and suffering from airway allergy even since many years before HIV infection. HIV-infected patients, undergoing HAART, are susceptible to atopic predispositions and chronic allergy and, subjects immunization may enhance T-cell responses [3].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
